Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 67 out of 100. Treatments

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Blood pressure variability (BPV) has been shown to have predictive value over blood pressure (BP) levels alone in stroke patients. We assessed whether BPV predicts cognitive and functional decline in Alzheimer disease, using data from a randomized trial (NILVAD [A European Multicentre Double-blind Placebo-controlled Phase III Trial of Nilvadipine in Mild to Moderate Alzheimer's Disease]). Patients with mild-to-moderate Alzheimer disease were included if they had ≥3 office BP measurements available to determine visit-to-visit BPV. Day-to-day BPV was assessed using home BP measurements in a subsample. The variation independent of mean was used to calculate BPV. Outcomes were change in Alzheimer's Disease Assessment Scale-cognitive subscale-12 and Disability Assessment for Dementia after 1 and 1.5 years. A total of 460 patients aged 72.1 (SD=8.1) years, with mean BP of 134.0/75.1 (10.9/6.3) mm Hg were included. After 1 year, patients in the highest quartile of BPV had deteriorated more on Alzheimer's Disease Assessment Scale-cognitive subscale compared with patients in the lowest quartile (systolic: β, 2.24 [95% CI, 0.11-4.38], P =0.040; diastolic: β, 2.54 [95% CI, 0.33-4.75] P =0.024). This association was still present after 1.5 years (systolic: β, 2.86 [95% CI, 0.35-5.36], P =0.026; diastolic: β, 3.30 [95% CI, 0.67-5.93], P =0.014). There was no effect of visit-to-visit BPV on Disability Assessment for Dementia. Day-to-day BPV was available for 46 patients. Significant associations were observed between day-to-day BPV and deterioration on Alzheimer's Disease Assessment Scale-cognitive subscale (systolic: P =0.036) and Disability Assessment for Dementia (systolic: P =0.020; diastolic: P =0.007) after 1 year, but not after 1.5 years. All associations were adjusted for potential confounders, including intervention group. In conclusion, this post hoc analysis indicates that higher visit-to-visit and day-to-day BPV might be associated with progression of Alzheimer disease. Targeting BPV may be a future target to slow decline in patients with Alzheimer disease. Clinical Trial Registration URL: https://www.clinicaltrials.gov. Unique identifier: NCT02017340.

What this study adds

Evidence grade: High

This is a trial of 460 participants. Day-to-day blood pressure variability was also associated with deterioration on cognition and disability measures.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

de Heus, R. A. A., Olde Rikkert, M. G. M., Tully, P. J., Lawlor, B. A., Claassen, J. A. H. R., & NILVAD Study Group. (2019). Blood Pressure Variability and Progression of Clinical Alzheimer Disease. Hypertension (Dallas, Tex. : 1979). https://doi.org/10.1161/hypertensionaha.119.13664

Vancouver

de Heus RAA, Olde Rikkert MGM, Tully PJ, Lawlor BA, Claassen JAHR, NILVAD Study Group. Blood Pressure Variability and Progression of Clinical Alzheimer Disease. Hypertension (Dallas, Tex. : 1979). 2019. doi:10.1161/hypertensionaha.119.13664. PMID: 31542965.

BibTeX

@article{deheus2019-31542965,
  author  = {de Heus, R. A. A. and Olde Rikkert, M. G. M. and Tully, P. J. and Lawlor, B. A. and Claassen, J. A. H. R. and {NILVAD Study Group}},
  title   = {{Blood Pressure Variability and Progression of Clinical Alzheimer Disease}},
  journal = {Hypertension (Dallas, Tex. : 1979)},
  year    = {2019},
  doi     = {10.1161/hypertensionaha.119.13664},
  pmid    = {31542965},
  url     = {https://doi.org/10.1161/hypertensionaha.119.13664}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

Using data from 460 patients with mild-to-moderate Alzheimer disease in a randomized trial, this study found that patients in the highest quartile of blood pressure variability had greater cognitive deterioration on the ADAS-cog after 1 and 1.5 years than those in the lowest quartile. Day-to-day blood pressure variability was also associated with deterioration on cognition and disability measures.

Study details

How this study scored 67/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 3 of 4; Study design 11 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 2 of 5; Sample size 2 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 2 of 2; Times cited 4 of 7; Citations per year 3 of 5; Impact for its field and year 4 of 6; Cited by studies here 1 of 6; Still being cited 2 of 4; Senior author's track record left out, no data; Institution's track record 1 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. 64 of the 96 points it could be judged on, which is 67 of 100. Total 67 of 100.64 of the 96 points we could judge = 67 of 100

Published in a peer-reviewed journal, and it is a randomized controlled trial. Scored zero for effect reported because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 64 of the 96 points we could judge it on, which is 67 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Hypertension (Dallas, Tex. : 1979))
Journal's citation record 3 / 4 Hypertension: journal h-index 369 (OpenAlex, 2026-10-29)
Study design 11 / 12 A randomized controlled trial
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 2 / 5 2019 — within 10 year(s) of the newest study here
Sample size 2 / 4 460 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 2 / 2 Randomized and blinded or placebo-controlled (as stated in the record)
Times cited 4 / 7 Cited 89 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 9.9 citations a year over 9 year(s) since 2019
Impact for its field and year 4 / 6 Cited 8.4× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 2 other studies in this library
Still being cited 2 / 4 Cited 31 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record 1 / 3 Radboud University Nijmegen: institution h-index 1,143 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 6 institution(s) in 3 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 31542965)
Free to read 0 / 2 Behind a paywall — scores zero
Points 64 / 96 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 64 of the 96 points we could judge it on is 67 out of 100.
Total 67 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — Unpaywall lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 13.

Later studies that cite this one

2 studies in the alzhub library list this one in their references.

Related studies in Treatments from nearby years

Also in Treatments

196 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.

Similar studies

More on Treatments

See all studies in Treatments →